Response to "No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study"

J Am Acad Dermatol. 2024 Aug 20:S0190-9622(24)02656-2. doi: 10.1016/j.jaad.2024.05.105. Online ahead of print.

¹ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Electronic address: deesha.desai@nyulangone.org.
² The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York; New York Medical College, Valhalla, New York.
³ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.

No abstract available

Keywords: breast cancer; malignancy; risk assessment; spironolactone.

Publication types